about
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosisTargeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosisCannabinoid signaling and liver therapeutics.Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liverHepatic fibrosis: molecular mechanisms and drug targets.Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.Elevated expression of osteopontin may be related to adipose tissue macrophage accumulation and liver steatosis in morbid obesityEnvironmental factors as disease accelerators during chronic hepatitis C.Cannabinoid receptors as therapeutic targets in the management of liver diseases.Chronic Exposure to Low Doses of Dioxin Promotes Liver Fibrosis Development in the C57BL/6J Diet-Induced Obesity Mouse Model.Pathophysiology of NASH: perspectives for a targeted treatment.The metabolic syndrome and chronic liver disease.Autophagy: a multifaceted partner in liver fibrosis.Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication.Autophagy in chronic liver diseases: the two faces of Janus.Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin.Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration.Macrophage autophagy protects against liver fibrosis in mice.ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.The Cannabinoid Receptor 2 Protects Against Alcoholic Liver Disease Via a Macrophage Autophagy-Dependent Pathway.M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.Upregulation of Epac-1 in Hepatic Stellate Cells by Prostaglandin E2 in Liver Fibrosis Is Associated with Reduced Fibrogenesis.Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C.Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts.Adipose tissue macrophages: MR tracking to monitor obesity-associated inflammation.Molecular mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in human hepatic myofibroblasts.Reply: To PMID 23728734.AJP-Cell begins a theme series on tissue fibrosis.Cigarette smoke exposure: a novel cofactor of NAFLD progression?Antifibrogenic role of the cannabinoid receptor CB2 in the liver.
P50
Q33464957-017FA572-FBBA-4E2D-97B8-2FA948457F62Q33947213-05272ECA-9E7B-4F51-B4EF-F6EBCFD0CBE3Q34337876-EF14B22F-2AEC-4444-98B9-5424DBACB864Q34794697-4C922974-E296-433C-A581-BE277C615900Q35911848-8580B6B8-ED17-4BA4-9F3A-D1A8C233B6B4Q36734955-10EEB8AB-19C0-43CF-8732-670C7276E4D1Q37023005-FF13B3F2-7EAB-4B83-B7C2-D685D09A672DQ37086429-7225AD00-62FE-4727-9DC9-A3755D992C25Q37405983-7420A9C2-DEEC-41FB-AE85-BD1D2814F3C8Q37674933-FF5EFE4E-AE47-4200-AEA5-1EA8ABBF6845Q37699476-04FFA36F-C841-43BD-9E55-A470A4EB9546Q38169739-5C94BD97-140D-4820-A87F-DA429C7D3A9EQ38254156-FA010197-7BEC-474C-B2D9-3744A06E0F6FQ38971509-63AEF1BA-2930-4B35-BFF9-3E544B70BBEFQ39024897-6064BF73-A841-412D-A7BA-0BC8215F478EQ39072337-9D7D84B2-ADEF-422D-B114-4D1ABFB4F5F1Q40001901-43FB9FC0-871D-472F-B680-7C8DA6D0B129Q41504958-31F13C31-2598-43BA-8972-4E77062B6A61Q41921041-985358F0-FC17-4C6D-BC4C-CE7B70B2CBFEQ42534041-B507B60E-8F00-4B17-BDD9-6DE2F7F63BA9Q42710363-A0C49B35-AE76-424A-AA2E-7F642E4D9487Q42797958-6B3E7478-EB66-43F9-B6AD-5EC38D3946A9Q43047280-02F2EBE9-8129-41C1-B1A2-19448D0A8390Q43476058-CAD73227-4B7D-4C42-BC24-54B0CB4E37E0Q44077314-C65063AC-0062-49C2-9532-4B00639971ACQ44909482-0B8B96F0-ACA5-4E6E-99F8-61F844E03BE9Q45035859-FAE62904-3840-452D-9ED1-7780E5618559Q45353406-E985626A-90CB-4233-959D-2D1229839276Q45365599-ACD045C8-5BBC-4B60-B142-C4AE95CDA981Q45930303-EE8EABC9-215E-4CE7-8B29-86A92807C774Q46376137-5ACFCA88-7797-4476-9070-17E62CE1D7F4
P50
name
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@fr
Sophie Lotersztajn
@nl
type
label
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@fr
Sophie Lotersztajn
@nl
prefLabel
Sophie Lotersztajn
@ast
Sophie Lotersztajn
@en
Sophie Lotersztajn
@es
Sophie Lotersztajn
@fr
Sophie Lotersztajn
@nl
P214
P21
P213
0000 0003 5944 8283
P214
P31
P735
P7859
viaf-220201378